Press Release Details

BEST Subsidiary RI Research Instruments Awarded $7.4 Million Contract for 40 Accelerating Structures for Swedish MAX IV Synchrotron

November 16, 2010

BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--RI Research Instruments GmbH, a majority-owned subsidiary of Bruker Energy & Supercon Technologies, Inc. (BEST), today announced the award of an approximately 5.5 million Euro (USD $7.4 million) contract from Lund University’s MAX-lab for the supply of 40 radio-frequency (rf) structures and related bunch compressing cavities for the linear accelerator (linac) of the MAX IV project.

MAX IV is intended to be the next generation synchrotron radiation facility in Sweden. The main sources at MAX IV are two storage rings (1.5 GeV and 3 GeV) with state-of-the-art production of soft and hard x-rays. The linac injector will also provide pulses to a short pulse facility. This solution allows the production of synchrotron radiation with optimal characteristics in a wide energy region, fulfilling the needs of many diverse research areas.

This contract covers the manufacturing and high rf power conditioning of 40 normal-conducting rf structures, together with 20 bunch compressing (SLED) cavities, together comprising the complete injection linac. The design is based on the 3 GHz accelerating structure design used for RI’s injection linacs previously supplied to major research laboratories in Switzerland, Great Britain, Australia, Germany, and in production for Taiwan, the Netherlands, and Brookhaven’s NSLS II in the United States. Delivery is expected between 2012 and 2013.

Dr. Michael Peiniger, Managing Director of RI Research Instruments, explained: “Manufacturing of normal conducting accelerating structures is complementary to our superconducting cavity business, and this award represents a milestone in further securing our base business.”

Hanspeter Vogel, Director of RI Research Instruments, added: “These accelerating structures will be delivered with high power conditioning ready for operation, strengthening our market position in terms of delivery of turnkey systems.”

About MAX-lab: MAX-lab is a national laboratory operated jointly by the Swedish Research Council and Lund University. MAX IV will be the next generation synchrotron radiation facility in Sweden. For more information:

About RI Research Instruments and Bruker Energy & Supercon Technologies, Inc.:

RI Research Instruments GmbH is a world leader in the development and manufacturing of normal and superconducting rf cavities and systems, linear accelerators, as well as special products for physics and energy research, scientific, medical and industrial applications. RI products also include high-performance electron and ion sources, particle beamlines and diagnostics, research reactor subunits as well as vacuum and cryogenic systems. BEST has operations in the US, the UK and Germany, and is a wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR).

For more information, please visit: or


This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “continue” or other similar words.

These forward-looking statements are predictions, not guarantees. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to materially differ from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those projected, include, but are not limited to, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as guarantees of future events.

The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

RI Research Instruments GmbH
Dr. Michael Peiniger, +49 2204 843676
Managing Director